Prostate Specific Antigen News and Research RSS Feed - Prostate Specific Antigen News and Research

American men have worse access to reproductive and sexual health care, shows research

American men have worse access to reproductive and sexual health care, shows research

Compared with women, American men have worse access to reproductive and sexual health care, research shows, a disparity fueled in part by the lack of standard clinical guidelines on the types and timing of exams, tests and treatments that should be offered to all men of reproductive age. [More]
Metabolic syndrome has inverse link with LUTS in Korean men

Metabolic syndrome has inverse link with LUTS in Korean men

The metabolic syndrome may be protective against lower urinary-tract symptoms, a study of Korean middle-aged men has found. [More]
Pathologists help determine prostate cancer patient’s eligibility for active surveillance

Pathologists help determine prostate cancer patient’s eligibility for active surveillance

Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. [More]
Viewpoints: Threat to drug development; GOP's Obamacare criticism tempered; finding doctors for seniors

Viewpoints: Threat to drug development; GOP's Obamacare criticism tempered; finding doctors for seniors

An invasive species has been introduced into the U.S. health innovation ecosystem, with a growing danger of permanent damage to the development of specialty drugs. [More]
BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

Among men with prostate cancer detected on screening, survival among those with a mutation in the BRCA2 gene is much poorer than in those without such a mutation, researchers report. [More]
MRI technology improves prostate cancer diagnosis

MRI technology improves prostate cancer diagnosis

Oncologists at UC San Diego Moores Cancer Center are the first in San Diego to meld magnetic resonance imaging (MRI) technology with a traditional ultrasound prostate exam to create a three-dimensional map of the prostate that allows physicians to view growths that were previously undetectable. [More]
Prostate cancer screening could cut deaths by one fifth

Prostate cancer screening could cut deaths by one fifth

Routine screening for prostate cancer could reduce the number of people who die from the illness by around a fifth, according to findings from a major European trial. [More]
Epigenetic test helps eliminate unnecessary repeat prostate biopsies

Epigenetic test helps eliminate unnecessary repeat prostate biopsies

More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed. Therefore there is a need to develop diagnostic tests that will help avoid unnecessary repeat biopsies. [More]
Sixteen cores better than 12 for prostate cancer detection

Sixteen cores better than 12 for prostate cancer detection

Sixteen-core prostate biopsy has a slightly higher cancer detection rate than 12-core biopsy, but with a similar safety profile and no increased detection of clinically insignificant tumours, study findings show. [More]
Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital. [More]
Six essential screening tests all men should receive during lifetime

Six essential screening tests all men should receive during lifetime

When it's comes men and health, the numbers don't stack up. Compared to women, men are 24 percent less likely than women to visit the doctor, according to the U.S. Department of Health & Human Services. Yet, men are 28 percent more likely than women to be hospitalized for congestive heart failure and 32 percent more likely to receive care for complication of diabetes. [More]
Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment. [More]
Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Improved diagnosis and management of one of the most common cancers in men - prostate cancer - could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease. [More]

Prostate biopsy method impacts cancer risk profile

Prostate cancers that are classified as “low risk” based on conventional prostate biopsy and histology are frequently found to be higher risk when assessed using the newer targeted biopsy method, US researchers have warned. [More]
ProMark test for prostate cancer meets primary endpoint

ProMark test for prostate cancer meets primary endpoint

Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease. [More]
New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group. [More]
Initial biopsy with epigenetic test rules out prostate cancer up to 88%

Initial biopsy with epigenetic test rules out prostate cancer up to 88%

A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many — if not most — men. [More]
Researchers design commercial test to rule out presence of genetic biomarkers of prostate cancer

Researchers design commercial test to rule out presence of genetic biomarkers of prostate cancer

A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many — if not most — men. [More]
FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [More]
Vitamin D deficiency predicts prostate biopsy outcomes

Vitamin D deficiency predicts prostate biopsy outcomes

Men with vitamin D deficiency are more likely than men with normal levels to test positive for prostate cancer on biopsy, and to have aggressive disease, US researchers have found. [More]